MesnaThird Party Manufacturing in India

Mesna (sodium 2-mercaptoethane sulfonate) works by detoxifying urotoxic metabolites produced by certain chemotherapy drugs.

After administration, mesna is rapidly oxidized in the blood to dimesna, an inactive compound. In the kidneys, dimesna is reduced back into the active free thiol form (mesna). This active thiol compound then binds directly to acrolein and other toxic metabolites of oxazaphosphorine chemotherapy agents (like ifosfamide and cyclophosphamide) in the urine.

Unlike general systemic antidotes, mesna acts specifically within the urinary tract. This targeted neutralization prevents severe damage to the bladder mucosa and effectively protects against hemorrhagic cystitis.

Therapeutic Uses

Mesna is prescribed for the treatment of:

• Hemorrhagic Cystitis Prophylaxis: Prevents bladder damage induced by high-dose ifosfamide chemotherapy.
• Cyclophosphamide Toxicity: Used prophylactically to reduce the incidence of urotoxicity associated with cyclophosphamide treatment.

Why Manufacturers Choose Mesna

Mesna is an indispensable supportive care medication in oncology. Any healthcare facility administering ifosfamide or high-dose cyclophosphamide relies heavily on mesna to ensure patient safety and prevent debilitating urinary complications.

This makes Mesna one of the most sought-after supportive molecules for third party manufacturing in India, with consistent demand from oncology-focused pharmaceutical companies and specialized hospital suppliers.